Loading…

A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats

The influence of an inhibitor of cAMP-dependent protein kinase and protein kinase C, H-7 [1-(5-isoquinolinesulfonyl)-2-methylpiperazine], on naloxone (an opioid receptor antagonist)-precipitated withdrawal signs and changes in levels of dopamine (DA) and its metabolites in morphine- or butorphanol-d...

Full description

Saved in:
Bibliographic Details
Published in:Brain research bulletin 2000-07, Vol.52 (5), p.363-369
Main Authors: Tokuyama, Shogo, Ho, Ing K, Yamamoto, Toshinori
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c421t-85bb9cb569291614716ee9a5423b2372566ffcecf02bfe68078b72fbd4daae9b3
cites cdi_FETCH-LOGICAL-c421t-85bb9cb569291614716ee9a5423b2372566ffcecf02bfe68078b72fbd4daae9b3
container_end_page 369
container_issue 5
container_start_page 363
container_title Brain research bulletin
container_volume 52
creator Tokuyama, Shogo
Ho, Ing K
Yamamoto, Toshinori
description The influence of an inhibitor of cAMP-dependent protein kinase and protein kinase C, H-7 [1-(5-isoquinolinesulfonyl)-2-methylpiperazine], on naloxone (an opioid receptor antagonist)-precipitated withdrawal signs and changes in levels of dopamine (DA) and its metabolites in morphine- or butorphanol-dependent rats was investigated. Animals were infused continuously with morphine (a μ-opioid receptor agonist) or butorphanol (a μ/δ/κ mixed opioid receptor agonist) for 3 days. Naloxone precipitated withdrawal syndrome and decreased the levels of DA in the cortex, striatum, and midbrain; 3,4-dihydroxyphenylacetic acid (DOPAC) in the cortex, striatum, limbic areas, and midbrain; and homovanilic acid (HVA) in the striatum, limbic areas, and midbrain regions. In animals rendered dependent on butorphanol, the results obtained were similar to those of morphine-dependent rats except for the changes in DOPAC levels. Concomitant infusion of H-7 and opioid blocked both the expression of withdrawal signs and the decreases in DA, DOPAC, and HVA levels in a dose-dependent manner. These results suggest that the enhancement of cAMP-dependent protein kinase and/or protein kinase C activity accompanying the increase of DA neuron activity during continuous infusion of opioids leads to an abrupt reduction in levels of DA and its metabolites precipitated by naloxone, which is intimately involved in the expression of physical dependence on opioids.
doi_str_mv 10.1016/S0361-9230(00)00273-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17731446</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0361923000002732</els_id><sourcerecordid>17731446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-85bb9cb569291614716ee9a5423b2372566ffcecf02bfe68078b72fbd4daae9b3</originalsourceid><addsrcrecordid>eNqFkd9qFTEQxoMo9rT6CEouRBS6mmR3k92rUkptCwUv1OuQP7OesbvJmuQUfQcf2j3uQb0rDGQgvy8z-T5CXnD2jjMu339iteRVL2r2hrG3jAlVV-IR2fBu36hGPSabv8gROc75G2NMdq18So4464Voebshv87pnGIBDPQOg8lAMWzRYonplF5X6pTaMbq7TIMZ448YoJoTOJyxmAKeuq0JXyEvIurjbCYMQE3wFEumExRj44hlvS9boDYZDJnGgcYZI_rKwwzBQyg0mZKfkSeDGTM8P5wn5MuHy88X19Xtx6ubi_PbyjWCl6prre2dbWUvei55o7gE6E3biNqKWolWymFw4AYm7ACyY6qzSgzWN94Y6G19Ql6v7y5f_76DXPSE2cE4mgBxlzVXquZNIxewXUGXYs4JBj0nnEz6qTnT-xj0nxj03mPN9rXEoMWie3kYsLMT-P9Uq-8L8OoAmOzMOCQTHOZ_XNN1ddcs2NmKweLGPULS2SEEBx6XFIr2ER_Y5DdgWaXK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17731446</pqid></control><display><type>article</type><title>A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats</title><source>ScienceDirect Journals</source><creator>Tokuyama, Shogo ; Ho, Ing K ; Yamamoto, Toshinori</creator><creatorcontrib>Tokuyama, Shogo ; Ho, Ing K ; Yamamoto, Toshinori</creatorcontrib><description>The influence of an inhibitor of cAMP-dependent protein kinase and protein kinase C, H-7 [1-(5-isoquinolinesulfonyl)-2-methylpiperazine], on naloxone (an opioid receptor antagonist)-precipitated withdrawal signs and changes in levels of dopamine (DA) and its metabolites in morphine- or butorphanol-dependent rats was investigated. Animals were infused continuously with morphine (a μ-opioid receptor agonist) or butorphanol (a μ/δ/κ mixed opioid receptor agonist) for 3 days. Naloxone precipitated withdrawal syndrome and decreased the levels of DA in the cortex, striatum, and midbrain; 3,4-dihydroxyphenylacetic acid (DOPAC) in the cortex, striatum, limbic areas, and midbrain; and homovanilic acid (HVA) in the striatum, limbic areas, and midbrain regions. In animals rendered dependent on butorphanol, the results obtained were similar to those of morphine-dependent rats except for the changes in DOPAC levels. Concomitant infusion of H-7 and opioid blocked both the expression of withdrawal signs and the decreases in DA, DOPAC, and HVA levels in a dose-dependent manner. These results suggest that the enhancement of cAMP-dependent protein kinase and/or protein kinase C activity accompanying the increase of DA neuron activity during continuous infusion of opioids leads to an abrupt reduction in levels of DA and its metabolites precipitated by naloxone, which is intimately involved in the expression of physical dependence on opioids.</description><identifier>ISSN: 0361-9230</identifier><identifier>EISSN: 1873-2747</identifier><identifier>DOI: 10.1016/S0361-9230(00)00273-2</identifier><identifier>PMID: 10922515</identifier><identifier>CODEN: BRBUDU</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology ; 3,4-Dihydroxyphenylacetic acid ; 3,4-Dihydroxyphenylacetic Acid - metabolism ; Analgesics ; Animals ; Behavior, Animal - drug effects ; Biological and medical sciences ; Brain - drug effects ; Brain - metabolism ; Butorphanol ; Butorphanol - administration &amp; dosage ; Cerebral Cortex - metabolism ; Corpus Striatum - metabolism ; Dopamine ; Dopamine - metabolism ; Enzyme Inhibitors - pharmacology ; H-7 ; homovanillic acid ; Homovanillic Acid - metabolism ; Injections, Intraperitoneal ; Injections, Intraventricular ; Limbic System - metabolism ; Male ; Medical sciences ; Mesencephalon - metabolism ; Morphine ; Morphine - administration &amp; dosage ; Naloxone - administration &amp; dosage ; Naloxone - antagonists &amp; inhibitors ; Neuropharmacology ; Opioid physical dependence ; Opioid-Related Disorders - metabolism ; Pharmacology. Drug treatments ; Protein Kinase Inhibitors ; Protein kinases ; Protein Kinases - metabolism ; Rats ; Rats, Sprague-Dawley</subject><ispartof>Brain research bulletin, 2000-07, Vol.52 (5), p.363-369</ispartof><rights>2000 Elsevier Science Inc.</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-85bb9cb569291614716ee9a5423b2372566ffcecf02bfe68078b72fbd4daae9b3</citedby><cites>FETCH-LOGICAL-c421t-85bb9cb569291614716ee9a5423b2372566ffcecf02bfe68078b72fbd4daae9b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23929,23930,25139,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1488384$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10922515$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tokuyama, Shogo</creatorcontrib><creatorcontrib>Ho, Ing K</creatorcontrib><creatorcontrib>Yamamoto, Toshinori</creatorcontrib><title>A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats</title><title>Brain research bulletin</title><addtitle>Brain Res Bull</addtitle><description>The influence of an inhibitor of cAMP-dependent protein kinase and protein kinase C, H-7 [1-(5-isoquinolinesulfonyl)-2-methylpiperazine], on naloxone (an opioid receptor antagonist)-precipitated withdrawal signs and changes in levels of dopamine (DA) and its metabolites in morphine- or butorphanol-dependent rats was investigated. Animals were infused continuously with morphine (a μ-opioid receptor agonist) or butorphanol (a μ/δ/κ mixed opioid receptor agonist) for 3 days. Naloxone precipitated withdrawal syndrome and decreased the levels of DA in the cortex, striatum, and midbrain; 3,4-dihydroxyphenylacetic acid (DOPAC) in the cortex, striatum, limbic areas, and midbrain; and homovanilic acid (HVA) in the striatum, limbic areas, and midbrain regions. In animals rendered dependent on butorphanol, the results obtained were similar to those of morphine-dependent rats except for the changes in DOPAC levels. Concomitant infusion of H-7 and opioid blocked both the expression of withdrawal signs and the decreases in DA, DOPAC, and HVA levels in a dose-dependent manner. These results suggest that the enhancement of cAMP-dependent protein kinase and/or protein kinase C activity accompanying the increase of DA neuron activity during continuous infusion of opioids leads to an abrupt reduction in levels of DA and its metabolites precipitated by naloxone, which is intimately involved in the expression of physical dependence on opioids.</description><subject>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology</subject><subject>3,4-Dihydroxyphenylacetic acid</subject><subject>3,4-Dihydroxyphenylacetic Acid - metabolism</subject><subject>Analgesics</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Butorphanol</subject><subject>Butorphanol - administration &amp; dosage</subject><subject>Cerebral Cortex - metabolism</subject><subject>Corpus Striatum - metabolism</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>H-7</subject><subject>homovanillic acid</subject><subject>Homovanillic Acid - metabolism</subject><subject>Injections, Intraperitoneal</subject><subject>Injections, Intraventricular</subject><subject>Limbic System - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mesencephalon - metabolism</subject><subject>Morphine</subject><subject>Morphine - administration &amp; dosage</subject><subject>Naloxone - administration &amp; dosage</subject><subject>Naloxone - antagonists &amp; inhibitors</subject><subject>Neuropharmacology</subject><subject>Opioid physical dependence</subject><subject>Opioid-Related Disorders - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Kinase Inhibitors</subject><subject>Protein kinases</subject><subject>Protein Kinases - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><issn>0361-9230</issn><issn>1873-2747</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFkd9qFTEQxoMo9rT6CEouRBS6mmR3k92rUkptCwUv1OuQP7OesbvJmuQUfQcf2j3uQb0rDGQgvy8z-T5CXnD2jjMu339iteRVL2r2hrG3jAlVV-IR2fBu36hGPSabv8gROc75G2NMdq18So4464Voebshv87pnGIBDPQOg8lAMWzRYonplF5X6pTaMbq7TIMZ448YoJoTOJyxmAKeuq0JXyEvIurjbCYMQE3wFEumExRj44hlvS9boDYZDJnGgcYZI_rKwwzBQyg0mZKfkSeDGTM8P5wn5MuHy88X19Xtx6ubi_PbyjWCl6prre2dbWUvei55o7gE6E3biNqKWolWymFw4AYm7ACyY6qzSgzWN94Y6G19Ql6v7y5f_76DXPSE2cE4mgBxlzVXquZNIxewXUGXYs4JBj0nnEz6qTnT-xj0nxj03mPN9rXEoMWie3kYsLMT-P9Uq-8L8OoAmOzMOCQTHOZ_XNN1ddcs2NmKweLGPULS2SEEBx6XFIr2ER_Y5DdgWaXK</recordid><startdate>20000715</startdate><enddate>20000715</enddate><creator>Tokuyama, Shogo</creator><creator>Ho, Ing K</creator><creator>Yamamoto, Toshinori</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20000715</creationdate><title>A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats</title><author>Tokuyama, Shogo ; Ho, Ing K ; Yamamoto, Toshinori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-85bb9cb569291614716ee9a5423b2372566ffcecf02bfe68078b72fbd4daae9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology</topic><topic>3,4-Dihydroxyphenylacetic acid</topic><topic>3,4-Dihydroxyphenylacetic Acid - metabolism</topic><topic>Analgesics</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Butorphanol</topic><topic>Butorphanol - administration &amp; dosage</topic><topic>Cerebral Cortex - metabolism</topic><topic>Corpus Striatum - metabolism</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>H-7</topic><topic>homovanillic acid</topic><topic>Homovanillic Acid - metabolism</topic><topic>Injections, Intraperitoneal</topic><topic>Injections, Intraventricular</topic><topic>Limbic System - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mesencephalon - metabolism</topic><topic>Morphine</topic><topic>Morphine - administration &amp; dosage</topic><topic>Naloxone - administration &amp; dosage</topic><topic>Naloxone - antagonists &amp; inhibitors</topic><topic>Neuropharmacology</topic><topic>Opioid physical dependence</topic><topic>Opioid-Related Disorders - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Kinase Inhibitors</topic><topic>Protein kinases</topic><topic>Protein Kinases - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tokuyama, Shogo</creatorcontrib><creatorcontrib>Ho, Ing K</creatorcontrib><creatorcontrib>Yamamoto, Toshinori</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Brain research bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tokuyama, Shogo</au><au>Ho, Ing K</au><au>Yamamoto, Toshinori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats</atitle><jtitle>Brain research bulletin</jtitle><addtitle>Brain Res Bull</addtitle><date>2000-07-15</date><risdate>2000</risdate><volume>52</volume><issue>5</issue><spage>363</spage><epage>369</epage><pages>363-369</pages><issn>0361-9230</issn><eissn>1873-2747</eissn><coden>BRBUDU</coden><abstract>The influence of an inhibitor of cAMP-dependent protein kinase and protein kinase C, H-7 [1-(5-isoquinolinesulfonyl)-2-methylpiperazine], on naloxone (an opioid receptor antagonist)-precipitated withdrawal signs and changes in levels of dopamine (DA) and its metabolites in morphine- or butorphanol-dependent rats was investigated. Animals were infused continuously with morphine (a μ-opioid receptor agonist) or butorphanol (a μ/δ/κ mixed opioid receptor agonist) for 3 days. Naloxone precipitated withdrawal syndrome and decreased the levels of DA in the cortex, striatum, and midbrain; 3,4-dihydroxyphenylacetic acid (DOPAC) in the cortex, striatum, limbic areas, and midbrain; and homovanilic acid (HVA) in the striatum, limbic areas, and midbrain regions. In animals rendered dependent on butorphanol, the results obtained were similar to those of morphine-dependent rats except for the changes in DOPAC levels. Concomitant infusion of H-7 and opioid blocked both the expression of withdrawal signs and the decreases in DA, DOPAC, and HVA levels in a dose-dependent manner. These results suggest that the enhancement of cAMP-dependent protein kinase and/or protein kinase C activity accompanying the increase of DA neuron activity during continuous infusion of opioids leads to an abrupt reduction in levels of DA and its metabolites precipitated by naloxone, which is intimately involved in the expression of physical dependence on opioids.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>10922515</pmid><doi>10.1016/S0361-9230(00)00273-2</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0361-9230
ispartof Brain research bulletin, 2000-07, Vol.52 (5), p.363-369
issn 0361-9230
1873-2747
language eng
recordid cdi_proquest_miscellaneous_17731446
source ScienceDirect Journals
subjects 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology
3,4-Dihydroxyphenylacetic acid
3,4-Dihydroxyphenylacetic Acid - metabolism
Analgesics
Animals
Behavior, Animal - drug effects
Biological and medical sciences
Brain - drug effects
Brain - metabolism
Butorphanol
Butorphanol - administration & dosage
Cerebral Cortex - metabolism
Corpus Striatum - metabolism
Dopamine
Dopamine - metabolism
Enzyme Inhibitors - pharmacology
H-7
homovanillic acid
Homovanillic Acid - metabolism
Injections, Intraperitoneal
Injections, Intraventricular
Limbic System - metabolism
Male
Medical sciences
Mesencephalon - metabolism
Morphine
Morphine - administration & dosage
Naloxone - administration & dosage
Naloxone - antagonists & inhibitors
Neuropharmacology
Opioid physical dependence
Opioid-Related Disorders - metabolism
Pharmacology. Drug treatments
Protein Kinase Inhibitors
Protein kinases
Protein Kinases - metabolism
Rats
Rats, Sprague-Dawley
title A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T11%3A42%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20protein%20kinase%20inhibitor,%20H-7,%20blocks%20naloxone-precipitated%20changes%20in%20dopamine%20and%20its%20metabolites%20in%20the%20brains%20of%20opioid-dependent%20rats&rft.jtitle=Brain%20research%20bulletin&rft.au=Tokuyama,%20Shogo&rft.date=2000-07-15&rft.volume=52&rft.issue=5&rft.spage=363&rft.epage=369&rft.pages=363-369&rft.issn=0361-9230&rft.eissn=1873-2747&rft.coden=BRBUDU&rft_id=info:doi/10.1016/S0361-9230(00)00273-2&rft_dat=%3Cproquest_cross%3E17731446%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-85bb9cb569291614716ee9a5423b2372566ffcecf02bfe68078b72fbd4daae9b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17731446&rft_id=info:pmid/10922515&rfr_iscdi=true